|
A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline |
Consulting or Advisory Role - NanoString Technologies (Inst) |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
Research Funding - Eisai (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Eisai (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - AstraZeneca; Roche |
Consulting or Advisory Role - Genomic Health |
Travel, Accommodations, Expenses - Genomic Health |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche/Genentech |
Consulting or Advisory Role - Roche/Genentech |
Research Funding - Celgene (Inst); Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
Consulting or Advisory Role - Novartis; Pierre Fabre |
Research Funding - Evgen (Inst) |
Travel, Accommodations, Expenses - Amgen |
|
|
Consulting or Advisory Role - Atossa Genetics |
Speakers' Bureau - Pfizer |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Pfizer |